BioCentury
ARTICLE | Finance

Another breath

Civitas leverages Phase IIa data for Arcus inhaled levodopa to raise $38 million

September 16, 2013 7:00 AM UTC

Civitas Therapeutics Inc. secured $38 million from investors that were impressed by proof-of-concept data showing the company's CVT-301 inhaled levodopa could treat motor fluctuations associated with Parkinson's disease.

The series B round was led by new investor Bay City Capital. New investors RA Capital and an undisclosed fund joined existing investors Alkermes plc (NASDAQ:ALKS); Canaan Partners; Fountain Healthcare Partners; and Longitude Capital...